Turning "Human Cells" into "Anti-cancer Drugs"! Taiwan is now the second nation in Asia to permit immune cell therapy.

Dr. Chiang Yu-Hoa, Hematology and Oncology, MacKay Memorial Hospital, who was a student at the University of Pennsylvania where CAR-T Laboratory is located, was present at the time the U.S. Food and Drug Administration announced that Novartis had obtained the drug permit. In addition to ushering in a new era of cancer treatment, the live broadcast of the FDA's approval of the drug permit opened the door to a new era of cancer treatment. With the liberalization of the policy, cancer patients in Taiwan finally saw a glimmer of hope!

As an example, Dr. Yi-Hao Jiang discussed the widespread disease known as non-Hodgkin's lymphoma. About 100 people in MacKay Memorial Hospital seek medical attention each year and a conservative estimate places the number of Taiwanese patients at around 3,000. The first-line treatment for this cancer type is usually aggressive because of its rapid growth and high malignancy. R-CHOP is basically the foundation of the treatment plan. However, past experience suggests that late-stage treatment is unsuccessful for roughly half of patients. The prognosis is extremely bleak once relapse has occurred.

The Ministry of Health and Welfare has approved the new generation of antibody-drug combinations and anti-CD20 monoclonal antibody chemotherapy as a dual-target combination (P-RCHP). The American Society of Hematology reported in 2021, based on data collected over a 28-month follow-up period, that among Asian populations, the 3-year profession-free survival of the control group receiving new-generation treatment exceeded 70%.

【Article Report】

Unknown back pain is revealed to be the result of diffuse large B-cell lymphoma!
The New Anti-Cancer Science: Immune Cell Therapy
Recent advances in CART-T research and new insights into its clinical applications
Exclusive/Cell Therapies Worth over NT$10 Million Soliciting Coverage by the National Health Insurance Program. MacKay Memorial Hospital reports that the symptoms of two lymphoma patients have completely subsided.

Yi-Hao Jiang

Senior attending physician

Main Info

專家觀點

新世代CAR-T細胞治療，精準毒殺癌細胞

CAR-T治療藉由基因工程，在病人T細胞上安裝可以鎖定癌細胞的導航標靶，再注回患者身上，開啟癌症治療的新時代！

CAR-T 11月底納健保給付｜嘉惠血液腫瘤病患

對癌症晚期病人，免疫療法已成為救命所繫，但費用卻成為難以跨越的障礙......因此健保署表示，CAR-T細胞治療法將正式納入健保！

新世代CAR-T 細胞治療｜顛覆血液腫瘤治療方式

一般復發的白血病患者治癒率不到三成，Emily才做完化療，就接受第二代CAR-T治療，成為全球第一起成功治癒案例！